Angiotensin III (human, mouse): RAAS Peptide for Cardiovascular and Neuroendocrine Research

Executive Summary: Angiotensin III (human, mouse) is a hexapeptide (Arg-Val-Tyr-Ile-His-Pro-Phe) derived from angiotensin II by N-terminal cleavage and serves as a key effector within the renin-angiotensin-aldosterone system (RAAS) (Oliveira et al., 2025). It mediates approximately 40% of angiotensin II’s pressor activity and fully retains aldosterone-stimulating capacity (APExBIO A1043). Angiotensin III interacts with both AT1 and AT2 receptor subtypes, showing relative specificity for AT2. Experimental evidence confirms its role in aldosterone secretion, renin suppression, and neuroendocrine signaling (Mechanistic Insights). High solubility, validated receptor specificity, and robust stability make APExBIO’s Angiotensin III (A1043) a reference standard for RAAS research workflows (Atomic Insights).

Biological Rationale

Angiotensin III is a naturally occurring peptide within the RAAS pathway. It is generated by the N-terminal cleavage of angiotensin II, primarily through the action of aminopeptidases in erythrocytes and various tissues [DOI]. Its sequence, Arg-Val-Tyr-Ile-His-Pro-Phe, is highly conserved across mammalian species. Angiotensin III retains full aldosterone-stimulating activity and exerts about 40% of the pressor effect compared to angiotensin II. Its physiological roles include regulation of blood pressure, aldosterone secretion, and modulation of central nervous system responses such as thirst and vasopressin release. The peptide acts at both AT1 and AT2 receptors, with a higher relative specificity for AT2, thereby influencing both vasoconstrictive and vasodilatory pathways. Angiotensin III’s dual receptor interaction supports its use in dissecting RAAS signaling and receptor-specific pharmacology.

Mechanism of Action of Angiotensin III (human, mouse)

Angiotensin III mediates its effects by binding to angiotensin II receptor subtypes AT1 and AT2. Upon binding AT1, it promotes vasoconstriction, sodium retention, and aldosterone synthesis. AT2 receptor activation counteracts many AT1-mediated effects, promoting vasodilation and anti-fibrotic responses [DOI]. Angiotensin III’s selectivity allows researchers to probe the balance between pressor and depressor arms of RAAS. In vitro, exogenous angiotensin III increases aldosterone secretion in adrenal cells and suppresses renin release in juxtaglomerular cells. In vivo, administration induces pressor and dipsogenic responses in rodent brain models. These effects are highly dependent on dose, receptor subtype availability, and tissue context. The peptide’s short sequence and defined receptor specificity make it a precise tool for modeling RAAS-driven cardiovascular and neuroendocrine phenomena.

Evidence & Benchmarks

• Angiotensin III (2–8) increases spike–AXL binding, potentially impacting viral pathogenesis (Oliveira et al., 2025, DOI).
• It mediates approximately 40% of the vasopressor activity of angiotensin II in vivo (APExBIO, product page).
• Angiotensin III elicits aldosterone secretion comparable to angiotensin II in adrenal bioassays (Mechanistic Insights, internal).
• It demonstrates full activity at both AT1 and AT2 receptors, with relative specificity for AT2 (Atomic Insights, internal).
• Solubility benchmarks: ≥23.2 mg/mL in water, ≥43.8 mg/mL in ethanol, ≥93.1 mg/mL in DMSO at 20–25°C (APExBIO, specification).
• Long-term storage stability is optimal at -20°C, desiccated; aqueous solutions are not recommended for extended storage (APExBIO, storage guide).

Applications, Limits & Misconceptions

Angiotensin III is used in cardiovascular research to dissect pressor mechanisms and aldosterone regulation. It enables detailed study of AT1 and AT2 receptor pathways in both in vitro and in vivo systems. The peptide is also leveraged in neuroendocrine models for understanding thirst, vasopressin release, and dipsogenic drive. Recent studies highlight its role in modulating viral receptor interactions, suggesting translational relevance for infection models [DOI]. However, angiotensin III is not a pan-agonist for all angiotensin-responsive systems. Its efficacy depends on receptor expression, tissue distribution, and local enzyme activity. The peptide does not substitute for angiotensin II in all contexts, especially where full pressor activity is required.

Common Pitfalls or Misconceptions

• Angiotensin III does not fully replicate angiotensin II’s pressor effect; its maximal activity is about 40% that of angiotensin II, so protocols requiring maximal vasoconstriction should use angiotensin II instead.
• It is not stable in aqueous solution for long-term storage; make fresh solutions before use and store solid peptide at -20°C, desiccated.
• Receptor selectivity is relative, not absolute; while it shows preference for AT2, Angiotensin III activates both AT1 and AT2, so downstream effects must be interpreted accordingly.
• Not all model organisms have identical RAAS enzyme and receptor expression; cross-species extrapolation requires validation.
• Angiotensin III is not a direct antiviral agent; its impact on viral binding is indirect via modulation of host cell receptors.

Workflow Integration & Parameters

APExBIO’s Angiotensin III (A1043) is supplied as a solid, with a molecular weight of 931.09 g/mol and formula C46H66N12O9. The peptide dissolves at ≥23.2 mg/mL in water, ≥43.8 mg/mL in ethanol, and ≥93.1 mg/mL in DMSO at room temperature (20–25°C). For optimal results, prepare aliquots in the chosen solvent just prior to use and avoid repeated freeze-thaw cycles. Store lyophilized peptide at -20°C, desiccated. Avoid long-term storage of diluted solutions. For cardiovascular or neuroendocrine assays, titrate dose based on receptor expression and tissue context. The product page (Angiotensin III (human, mouse)) provides expanded protocols and quality control data. For troubleshooting, refer to workflow guides such as Workflow Reliability for Angiotensin III, which details protocol compatibility and vendor selection—a resource that complements the current article by focusing on operational best practices rather than mechanistic detail.

Compare with Mechanistic Insights for Angiotensin III, which emphasizes detailed receptor pharmacodynamics, while this article provides a broader evidence synthesis and workflow context. For translational scope, see Mechanistic Leverage and Strategic Opportunities, which extends into viral and disease modeling frameworks, whereas the present review is focused on core RAAS and neuroendocrine mechanisms.

Conclusion & Outlook

Angiotensin III (human, mouse) is a validated tool for dissecting RAAS function, receptor pharmacology, and neuroendocrine signaling. Its unique balance of pressor and aldosterone-stimulating activity, combined with high solubility and storage robustness, position it as a reference standard for cardiovascular and neuroendocrine research. Ongoing studies are expanding its utility into viral receptor interaction models. For reproducible results and regulatory compliance, source Angiotensin III (human, mouse) directly from APExBIO and follow established workflow recommendations.